Vital Therapies Inc. (NASDAQ:VTL) Given Consensus Rating of “Hold” by Analysts
Vital Therapies Inc. (NASDAQ:VTL) has been assigned a consensus recommendation of “Hold” from the six research firms that are covering the stock. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.67.
Several research firms have issued reports on VTL. Canaccord Genuity restated a “buy” rating and set a $10.00 target price on shares of Vital Therapies in a research report on Thursday, August 4th. Zacks Investment Research downgraded Vital Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th.
Shares of Vital Therapies (NASDAQ:VTL) opened at 5.86 on Tuesday. Vital Therapies has a 12 month low of $3.17 and a 12 month high of $11.80. The company’s 50-day moving average price is $6.09 and its 200-day moving average price is $7.58. The company’s market cap is $184.82 million.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. During the same period in the prior year, the business earned ($0.63) EPS. Analysts anticipate that Vital Therapies will post ($1.29) EPS for the current year.
In other Vital Therapies news, Director Faheem Hasnain acquired 118,243 shares of the stock in a transaction that occurred on Friday, August 12th. The shares were bought at an average price of $5.92 per share, for a total transaction of $699,998.56. Following the completion of the transaction, the director now owns 122,743 shares of the company’s stock, valued at approximately $726,638.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 29.88% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its position in Vital Therapies by 4.1% in the second quarter. ProShare Advisors LLC now owns 26,157 shares of the company’s stock worth $162,000 after buying an additional 1,037 shares in the last quarter. Rhumbline Advisers boosted its position in Vital Therapies by 55.8% in the second quarter. Rhumbline Advisers now owns 30,352 shares of the company’s stock worth $188,000 after buying an additional 10,876 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Vital Therapies by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 507,446 shares of the company’s stock worth $3,146,000 after buying an additional 12,021 shares in the last quarter. BlackRock Fund Advisors boosted its position in Vital Therapies by 7.3% in the second quarter. BlackRock Fund Advisors now owns 1,014,160 shares of the company’s stock worth $6,288,000 after buying an additional 68,969 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its position in Vital Therapies by 10.3% in the second quarter. BlackRock Investment Management LLC now owns 87,566 shares of the company’s stock worth $543,000 after buying an additional 8,189 shares in the last quarter. 27.88% of the stock is currently owned by institutional investors and hedge funds.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.